[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-438559-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-438559-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","preparation-and-evaluation-of-lactoferrin-modified-curcumin-long-circulating-nanoliposomes-for-hypoxic-brain-injury-therapy","Preparation and evaluation of lactoferrin-modified curcumin long-circulating nanoliposomes for hypoxic brain injury therapy","","Nanoscale Advances paper investigates curcumin (Cur) liposome formulations to overcome rapid elimination, inefficient delivery, and poor biodistribution. Cur-L, Cur-LCL, and lactoferrin (Lf)-modified Cur-LCL (Lf-Cur-LCL) are prepared by ethanol injection and evaluated in a hypoxic brain injury context. HE staining and immunohistochemistry assess tissue damage and apoptosis biomarkers. All formulations show reduced particle size and good stability, enhanced release versus free Cur, prolonged in vivo retention, improved oxygenation, elevated superoxide dismutase, reduced malondialdehyde, and the strongest therapeutic effect from Lf-Cur-LCL.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/preparation-and-evaluation-of-lactoferrin-modified-curcumin-long-circulating-nanoliposomes-for-hypoxic-brain-injury-therapy/438559/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/preparation-and-evaluation-of-lactoferrin-modified-curcumin-long-circulating-nanoliposomes-for-hypoxic-brain-injury-therapy/438559.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What problem does the study address with curcumin nanoformulations?","Question",{"text":62,"@type":63},"Curcumin formulations face fast in vivo elimination, inefficient delivery, and inadequate biodistribution to target sites.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How are the different liposome formulations prepared and compared?",{"text":67,"@type":63},"Cur-L, Cur-LCL, and Lf-Cur-LCL are prepared using ethanol injection, then evaluated for size, stability, in vitro release, and in vivo retention in a hypoxic brain injury context.",{"name":69,"@type":60,"acceptedAnswer":70},"What key therapeutic effects are reported, and which formulation performs best?",{"text":71,"@type":63},"The formulations improve oxygen-related parameters, modulate oxidative stress markers (increased superoxide dismutase and decreased malondialdehyde), and show reparative effects on liver, brain, and spleen damage; Lf-Cur-LCL shows the most significant therapeutic effect.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},438559,1790785921,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Nanoscale Advances  \nPAPER  \nCite this: DOI: 10 .1039/d5na00521c  \nReceived 28th May 2025  \nAccepted 6th November 2025 DOI: 10.1039/d5na00521c[rsc.li/nanoscale-advances](rsc.li/nanoscale-advances)  \nPreparation and evaluation of lactoferrin-modifiedcurcumin long-circulating nanoliposomes for hypoxic brain injury therapy  \nYu Xue,a Jinjie Liu,b Faisal Raza,  c Hajra Zafar,c Hong Zhao,d Ran Lie and Zanhua Liu  *f  \nNanoformulations of curcumin (Cur) are advanced but still have shortcomings in terms of fast in vivo elimination, inefficient delivery and biodistribution of drugs to target sites. Herein, Cur liposomes (Cur-L), Cur long-circulating liposomes (Cur-LCL), and lactoferrin (Lf)-modified Cur long-circulating liposomes (Lf-Cur-LCL) were prepared using ethanol injection before application in hypoxic brain injury. Hematoxylin-eosin (HE)-stained pathological sections of the brain, liver, and spleen were examined to assess the extent of tissue damage and efficacy of treatments. Additionally, immunohistochemical staining of brain tissue was performed to assess the expression of key biomarkers involved in apoptosis. The prepared Cur-L, Cur-LCL and Lf-Cur-LCL displayed smaller particle sizes, good polymer-dispersity index, and stability over one week. The in vitro release behavior of Cur-L, Cur-LCL, and Lf-Cur-LCL was significantly better than that of Cur, with Cur-LCL and Lf-Cur-LCL showing better sustained release effects. Also, Cur-L, Cur-LCL, and Lf-Cur-LCL significantly prolonged the retention time of Cur in vivo with Lf-Cur-LCL significantly increasing Cur content in brain tissues. Furthermore, Cur-L, Cur-LCL, and Lf-Cur-LCL increased the partial pressure of oxygen and decreased the partial pressure of carbon dioxide in chronic intermittent hypoxia model mice. These formulations also elevated levels of superoxide dismutase and reduced malondialdehyde levels in the model group. Furthermore, they also demonstrated a reparative effect on liver, brain, and spleen damage induced by the model, with Lf-CurLCL showing the most significant therapeutic effect. In conclusion, the prepared Lf-Cur-LCL exhibited brain-targeting properties and showed considerable potential for treating brain diseases, thus providing theoretical support for clinical development and application of curcumin.  \n1 Introduction  \nObstructive sleep apnea-hypopnea syndrome (OSAHS) is a common chronic condition in otorhinolaryngology1 with roughly one billion individuals affected globally.2,3 Its primary pathophysiological mechanism is chronic intermittent hypoxia (CIH), which is characterized by partial or complete collapse of the upper airway during sleep, leading to reduced oxygen levels, apneic events, or hypopnea.4 This results in transient airway reopening, followed by hyperventilation and normalization of  \naDepartment of Clinical Stage 1 Experimental Ward, Shanghai Pudong new area  \nPeople's Hospital, Shanghai 201299, [China. E-mail: Xueyu@shpdph.com](China. E-mail: Xueyu@shpdph.com)  \nbDepartment of General Practice Ward, Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian 116033, Liaoning, China cSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China dDepartment of Neurology, Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian 116033, Liaoning, China eDepartment of Pharmaceutics, School of Pharmacy, Jiangsu University, Zhenjiang 212016, Jiangsu, China  \nfDepartment of Neurology, Shanghai Pudong new area People's Hospital, Shanghai  \n201299, China. E-mail: [liuzanhua@shpdph.com](liuzanhua@shpdph.com)  \n© 2025 The Author(s) . Published by the Royal Society of Chemistry  \nblood oxygen saturation, but the individual can experience repeated airway obstruction and hypoxia upon reentry into sleep. This cyclical hypoxia-reoxygenation process resembles the ischemia-reperfusion injury mechanism and signi􀀁cantly impacts human health.5  \nOSA is an independent risk factor for ","cbCaicZ8nmtrha3H","https://ap.wps.com/l/cbCaicZ8nmtrha3H","pdf",1519277,17,"English","# Introduction\n## Hypoxic mechanisms and OSAHS context\n## Limitations of current OSA treatments\n## Curcumin and targeted nanoformulation rationale","[{\"question\":\"What problem does the study address with curcumin nanoformulations?\",\"answer\":\"Curcumin formulations face fast in vivo elimination, inefficient delivery, and inadequate biodistribution to target sites.\"},{\"question\":\"How are the different liposome formulations prepared and compared?\",\"answer\":\"Cur-L, Cur-LCL, and Lf-Cur-LCL are prepared using ethanol injection, then evaluated for size, stability, in vitro release, and in vivo retention in a hypoxic brain injury context.\"},{\"question\":\"What key therapeutic effects are reported, and which formulation performs best?\",\"answer\":\"The formulations improve oxygen-related parameters, modulate oxidative stress markers (increased superoxide dismutase and decreased malondialdehyde), and show reparative effects on liver, brain, and spleen damage; Lf-Cur-LCL shows the most significant therapeutic effect.\"}]","Preparation and evaluation of lactoferrin-modified curcumin long-circulating nanoliposomes for hypoxic brain injury therapy | PDF",1790685708,43]